Market Cap (In USD)
13.87 Million
Revenue (In USD)
68 Thousand
Net Income (In USD)
-21.66 Million
Avg. Volume
10.45 Thousand
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 0.26-2.63
- PE
- -
- EPS
- -
- Beta Value
- 7.767
- ISIN
- US1140822099
- CUSIP
- 114082209
- CIK
- 748592
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Sanjeev Luther
- Employee Count
- -
- Website
- https://www.brooklynitx.com
- Ipo Date
- 1991-08-29
- Details
- Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company also develops therapies using gene-editing and cell therapy technology for the treatment of oncology, blood disorder, and monogenic disease. Brooklyn ImmunoTherapeutics, Inc. is based in Brooklyn, New York.
More Stocks
-
SNA
-
ARBV
-
3202
-
OZKBank OZK
OZK
-
603889Zhejiang Xinao Textiles Inc.
603889
-
WMNNFAston Minerals Limited
WMNNF
-
RGBDRegional Brands Inc.
RGBD
-
TRX